MAM
Twitter to address Elon Musk’s demands by providing crucial tweet data
MUMBAI: In a bid to end the standoff between the company and Elon Musk, Twitter will grant Tesla’s CEO unprecedented access to its “firehose” of public tweet data, The Washington Post reported. With this, the tech giant seeks to assuage Musk’s concerns over fake or automated accounts by yielding access to the firehose API, which contains ‘every tweet as it is posted.’
Twitter’s firehose API, in its entirety, shows what a user would see if they followed every account on Twitter — although the sheer volume of data is impossible to obtain or analyse without automation. Due to its value for ad-targeting and platform surveillance, it is also one of the company’s most closely held resources.
Firehose data could be immensely valuable as raw material for a study on automated activity. However, conducting a full study of automated activity would require significant time and resources, given the sheer scale of the data.
Providing valuable data could help Twitter score political points over Musk, as the micro networking platform seeks to fend off Musk’s qualms over the number of bots or automated accounts on the platform, and ensure that he honours his part of the buyout deal.
The news comes just days after the maverick billionaire once again threatened to back out of his deal to purchase Twitter, accusing it of failing to provide data on fake accounts.
In his filing with the US Securities Exchange on Monday, Musk accused Twitter of breaching its April agreement by not providing him sufficient data on automated accounts, rejecting the company’s offer to provide more detail on its internal studies of the issue.
Musk legally committed to purchasing Twitter in April this year, but since then has been increasingly vocal about growing bot activity on the platform, in what is seen by many as an attempt to renegotiate the deal on more favourable terms or cancel it altogether.
ALSO READ |The Twitter-Elon Musk tussle: To be ‘bot’ or not to be
“Twitter’s latest offer to simply provide additional details regarding the company’s testing methodologies is tantamount to refusing Musk’s data requests,” Musk’s representatives said in the filing. “At this point, Musk believes Twitter is transparently refusing to comply with its obligations under the merger agreement.”
Despite all this, Twitter Inc. remains confident the deal will proceed as planned. In an internal meeting, a senior company executive assured employees that the deal was proceeding normally and set for a shareholder vote in late July or early August.
Meanwhile, the networking giant’s stock continues to trade well below the $54.20 price set by Musk, reflecting market skepticism that the deal will go through as agreed.
In response to Musk’s SEC filing, Twitter issued a statement earlier this week. “Twitter has and will continue to cooperatively share information with Musk to consummate the transaction by the terms of the merger agreement,” the statement reads. “We intend to close the transaction and enforce the merger agreement at the agreed price and terms.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
